Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines

    Related Topics:

    1. France pegs Gilead hepatitis C drug at "lowest price in Europe"

      Headlines

      Thu, 20 Nov 2014

      PARIS, Nov 20 (Reuters) - France has negotiated a big discount for Gilead Sciences Inc 's controversial new hepatitis C drug Sovaldi, under a government deal that ensures it will be fully reimbursable by health-funding schemes.

    2. Drug spending tops $1 trln on hepatitis C, cancer therapies -study

      Headlines

      Thu, 20 Nov 2014

      Nov 20 (Reuters) - Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc 's Sovaldi...

    3. Gilead hepatitis C drug highly effective in cirrhosis patients

      Headlines

      Tue, 11 Nov 2014

      Nov 11 (Reuters) - Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.

    4. RPT - INSIGHT-After hep C cure, companies target next big liver disease market

      Headlines

      Mon, 10 Nov 2014

      Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins

    5. Merck 4-week hep C regimen with Gilead's Sovaldi comes up short

      Headlines

      Sun, 9 Nov 2014

      Nov 9 (Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc 's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a

    6. INSIGHT-After hep C cure, companies target next big liver disease market

      Headlines

      Sun, 9 Nov 2014

      Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins

    7. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

      Headlines

      Tue, 4 Nov 2014

      the team has made good picks in the health-care and other sectors, including top-five holdings Amgen AMGN, Gilead Sciences GILD , and Altria MO. This fund, therefore, has returned 4% and has outpaced 81% of its counterparts for the year

    8. UPDATE 2- Gilead third-quarter Sovaldi sales dip, but net profit triples

      Headlines

      Tue, 28 Oct 2014

      Oct 28 (Reuters) - Gilead Sciences Inc , maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.

    9. Gilead third-quarter profit triples as sales more than double

      Headlines

      Tue, 28 Oct 2014

      Oct 28 (Reuters) - Gilead Sciences Inc , maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.

    10. The Ones That Got Away

      Video Reports

      Fri, 26 Sep 2014

      fair value estimate. The other one is [TICKER: GILD ] Gilead Sciences ( GILD ), which I was looking at around June-July of ..... potential longer-term risks. Glaser: And what about Gilead ? How has it changed the way that you think about

      Gilead Sciences found at 2:17

      a pretty steep discount to Morningstar's fair value estimate. The other one is [TICKER: GILD ] Gilead Sciences ( GILD ), which I was looking at around June-July of last year. In that case, the stock was actually up about 100% from the
    « Prev12345Next »
    Content Partners